<DOC>
	<DOCNO>NCT00644280</DOCNO>
	<brief_summary>To determine whether ranibizumab therapy tube insertion glaucoma surgery maintain patency tube prevent scar formation , increase chance successful procedure compare observation .</brief_summary>
	<brief_title>Ranibizumab Preventing Failure Ahmed Valve Glaucoma Surgery</brief_title>
	<detailed_description>This randomize , open-label , Phase I/II study intravitreally administer ranibizumab treatment tube patency glaucoma patient . Thirty ( 30 ) patient severe glaucoma require tube randomize ( 2:1 ) either ranibizumab observation . Consented , enrolled subject assign treatment group receive open-label intravitreal injection 0.5 mg ranibizumab 1 week prior tube insertion monthly x 2 injection Sham intravitreal injection observation group NOT perform . Study period : Study start date : May 1st , 2007 ( estimate ) Enrollment period : 6-8 month ( estimate ) Follow-up period : 6 month Study end Date : December 1st , 2010 ( estimate )</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1. ability provide write informed consent comply study assessment full duration study . 2. age â‰¥ 21 3. diagnosis glaucoma determine candidate therapy tube insertion . 1. pregnant lactate female 2 . Persons oral contraceptive woman childbearing age 3. prior enrollment study 4. condition investigator believe would pose significant hazard subject investigational therapy initiate 5. participation another simultaneous medical investigation trial 6. history active inflammatory , infectious , idiopathic keratitis preclude view anterior segment structure 7. previous injection ranibizumab either eye . 8 . Persons Plavix ( clopidogrel bisulfate ) coumadin 9 . Persons uncontrolled high blood pressure 10 . Persons renal liver disease</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Glaucoma , Ahmed Valve</keyword>
</DOC>